Pressing Ranbaxy for Answers on, Changes to its Handling of Valacyclovir Distribution

NCPA has been inundated with additional complaints from independent community pharmacists who have found it impossible to obtain valacyclovir (the generic version of Valtrex) for their patients, even when national chain pharmacies nearby are stocking it.  We recently relayed those concerns and some questions to the drug’s manufacturer, Ranbaxy, via a letter which we also shared with the Federal Trade Commission and the U.S. House Energy and Commerce Committee.

A number of wholesalers can’t get the drug either, fueling speculation that the manufacturer struck a direct-to-large-chain deal giving them exclusive access. More on why that’s bad for patients and independent pharmacists alike can be found in a previous post.

Last Friday, in his weekly Executive Update to NCPA members, Bruce Roberts recounted the valacyclovir situation. Almost immediately, pharmacists began responding en masse, echoing the problems and adding more details.

That same day NCPA wrote to Ranbaxy officials again. We asked Ranbaxy for a reply by Feb. 10; the manufacturer indicated it may need a few more days due to the snowstorm affecting the east coast. Here’s a copy of the letter:

February 5, 2010

Mr. Ahmad T. Aboelezz, Esq.
Ranbaxy, Inc

600 College Road East, Suite 2100

Princeton, NJ 08540

Re:       Concerns about restricted distribution of valacyclovir

Dear Mr. Aboelezz,

Thank you for your February 2 e-mail reply to NCPA’s December 17, 2009 letter expressing concerns about Ranbaxy’s decision to pursue what appears to be a discriminatory distribution business model.  We understand and acknowledged in our initial letter Ranbaxy’s contention that there are raw material shortages in the production of valacyclovir. However, FDA does not have valacyclovir on its official list of drugs in short supply, which often cites a lack of raw material as the reason for a shortage. Your email reply did not address our central concern that Ranbaxy has decided to bypass wholesaler distribution to all community pharmacies by striking an exclusive arrangement to distribute valacyclovir to large publicly traded pharmacy chains.

While we are concerned about discriminating against non-publicly traded pharmacies, our pharmacy members have properly expressed concern over disadvantaging patients, and private and government payors by forcing them to pay for brand name Valtrex.  Your email reply states that, “Ranbaxy has tried its best to distribute product in such a way that provides product access as broadly as possible given the limited supply.”  It would be insightful to see the mapping analysis performed by Ranbaxy to support the notion that the chosen limited distributed model provide product access as broadly as possible and we respectfully request a copy of that documentation (and will gladly sign a mutually agreeable confidentiality agreement if necessary prior to doing so).  Further, we ask for your response to why the product was not distributed through wholesalers.  Publicly traded chains contract with wholesale distributors and, ostensibly, would have had the same access to product as the rest of the marketplace. This would have seemed to be the most equitable way to broadly distribute the product rather than indiscriminately picking certain companies.

Your decision to shut out community pharmacies seems even more curious as Consumer Reports® and other consumer surveys have shown that they receive better service in community pharmacies than by the publicly traded chains.  Independent community pharmacies purchase over $60 billion in prescription pharmaceuticals annually.  We presume that this is a market worthy of Ranbaxy’s attention; however, your decision to shut community pharmacies out in favor of the publicly traded chains leads us to have to conclude that Ranbaxy has made the business decision to ignore this part of the marketplace.

In addition to our requests for information about the patient access mapping analysis and to support the decision to bypass the traditional pharmaceutical distribution model, we request that you immediately alert plans and payors that valacyclovir is available only on a limited distribution basis only and that the majority of retail community pharmacies do not have access to the product.

It took over six weeks to receive your last response, we ask for your response to these questions by February 10.


Bruce T. Roberts, R.Ph.

CEO National Community Pharmacists Association

cc: Bill Winter, Ranbaxy, VP Sales

Stuart L. Soberman, Esq., NCPA SVP and Chief Legal Officer

The Honorable Henry Waxman, Chairman, House Energy and Commerce Committee

The Honorable Jon Leibowitz, Commissioner, FTC

4 Responses to “Pressing Ranbaxy for Answers on, Changes to its Handling of Valacyclovir Distribution”

  1. 1 BILL REGEL, DPH February 14, 2010 at 10:45 am


  2. 2 DON BAR March 19, 2010 at 8:14 am

    I need a simple answer. I receive my Valtrex though Medco Mail for a 90 day supply. They keep telling me that they do not have the generic form of the drug and my cost is allot because it is not generic. Can someone please tell me if this will be available in the next several months so I do not by more than I need. I take the drug to ward of symptoms of herpies.

    • 3 ncpa1 March 22, 2010 at 3:10 pm

      Only the drug manufacturers can predict when the supply will catch up with the demand, so unfortunately we can’t give you a simple answer. We recommend you see a community pharmacist in your area, who may be able to get you a shorter supply of the costlier, name brand Valtrex until the supply shortage of the generic eases. Ranbaxy, the company manufacturing Valacyclovir, the generic substitute for Valtrex, has exclusive rights to sell the generic Valtrex until May. Hopefully, by then there will be an adequate supply of Valacyclovir or other generic alternatives. Here is a map of independent pharmacies across the country that will help your search, simply input your zip code at this site

  3. 4 Barbara May 20, 2010 at 4:00 pm

    I have also been having a very difficult time getting Valcyclovir and I use a large pharmacy. They have been unable to even give a guess as to delivery dates.

    I have requested that my MD rewrite my prescription for Valtrex with no substitutions even though this will be a greater expense to me.

    I use Valtrex for Herpes Whitlow and have not had any hospitalizations since starting it 3 years ago. I do seem to notice some dizziness with using the generic that I did not have with Valtrex

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

Search by Categories

%d bloggers like this: